Beximco Pharmaceuticals announced it would acquire 54.6 per cent shares in Sanofi Bangladesh. The base price for the transaction agreed between Sanofi Group and Beximco Pharma is £35.5m but it may go up to £40m. The proposed acquisition is subject to government's clearance including necessary approval of the transaction by the Bangladesh Bank and completion of a definitive sale and purchase agreement. Industries ministry holds nearly 25.36 percent and Bangladesh Chemical Industries Corporations holds around 19.96 percent shares of Sanofi Bangladesh. "We are delighted to announce the proposed acquisition of a majority stake in Sanofi Bangladesh. If approved, it will be the second strategic acquisition in the company's history, following that of Nuvista Pharma Limited (formerly Organon Bangladesh) in 2018," said Beximco Pharma Managing Director Nazmul Hassan. "This acquisition of Sanofi Bangladesh will serve as a strong foundation for sustainable growth in the futu...